DNCB Test in Cancer Patients

Publisher Website
Google Scholar
Abstract
To the Editor: The need for a standardized method of interpreting the DNCB skin test in patients with cancer was recently stressed by Catalona et al.1 Their unique approach in grading response is appealing, but may not represent an optimum method for detecting sensitization to DNCB.In testing over 50 patients with advanced cancer with DNCB, we used 1000 μg for initial sensitization, followed in two to three weeks with rechallenge doses of both 100 μg and 1000 μg. A majority of patients (75 per cent) reacted to the larger rechallenge dose, but very few (15 per cent) to a . . .